Nexsan Exceeds First Quarter Revenue Target and Announces Plans to Foster More Growth and Continued Innovation on Marquee SAN and File Storage Product Line
10.5.2023 16:00:00 EEST | Business Wire | Press release
Nexsan today announced that it surpassed its aggressive Q1 earnings target. After being acquired by Serene Investment Management LLC in February, Serene’s ownership has quickly steered Nexsan back into a stage of growth, innovation, and profitability.
Under this new ownership, Serene Investment Management LLC’s first order of business was to bring in experienced technology leaders to foster a new era of growth and deliver on the ownership’s vision of continued high-quality product innovation, delivery, and unrivaled customer satisfaction. One of those experienced technology leaders is Nexsan’s new CEO, Dan Shimmerman, who has a proven track record of success in delivering strategic vision, execution, and value for all stakeholders in enterprise technology.
“The future is incredibly bright for all of Nexsan which includes our loyal customers and partners,” explains Nexsan CEO, Dan Shimmerman. “Serene’s ownership is committed to investing in the business and fueling continuous growth. We’ve been given the vital capital we need to continue to innovate and deliver the highly-reliable, cost-effective data storage solutions that have been exceeding specific and crucial business demands for over 20 years.”
As part of the acquisition earlier this year, Serene retained key employees and leaders to ensure business continuity and deliver on Nexsan’s commitment to a seamless customer support experience. Throughout the acquisition and restructuring, Serene has been steadfastly committed to maintaining Nexsan’s high level of customer support which includes the support team’s global coverage and footprint.
In the interim, Nexsan negotiated strong strategic alliance agreements with their global partner network to stabilize supply chains and kick-start its continued service to all end customers and vendors.
Earlier in the month of April, Nexsan also attended the NAB (National Association of Broadcasters) Show Centennial in Las Vegas, Nevada to showcase the reliability, cost-effectiveness, and continued innovation on its marquee SAN and file storage product line that includes E-Series, Unity, and the exciting developments on its Assureon Data Vault.
For more information on Nexsan’s suite of enterprise storage products, see https://www.nexsan.com/products-landing/.
For more information on Nexsan’s core use cases, see https://www.nexsan.com/whats-your-business/.
About Nexsan®
Nexsan® is a global leader in enabling customers to securely store, protect and manage data. Established in 1999, Nexsan has earned a reputation for delivering the most highly reliable, secure and cost-effective storage, while always remaining agile in order to continuously deliver purpose-built storage and data management solutions that meet complex and everchanging IT, business and budgetary requirements. Nexsan’s patented technology is ideal for a variety of use cases including Financial, Healthcare and Life Sciences, Government, Military, Law Enforcement, Education, Media and Entertainment and Call Centers. For further information, please visit: www.nexsan.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005029/en/
Contact information
Matthew Pugh
443-527-1552
mpugh@pughandtillerpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom